PR Newswire·May 21, 2026, 8:00 AM ET

TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY

Tyra Biosciences and the Bladder Cancer Advocacy Network (BCAN) established Upper Tract Urothelial Cancer (UTUC) Awareness Day on May 21, 2026, to raise disease recognition & highlight the need for innovation.
UTUC is a rare cancer affecting the kidney & ureter lining with a high prevalence of FGFR3 alterations & currently lacks an established systemic standard of care.
Standard treatments often involve endoscopic ablation or nephroureterectomy, which can cause long-term complications & result in kidney loss.
Tyra is dosing patients with dabogratinib, an investigational oral FGFR3-selective inhibitor, in the Phase 2 SURF303 study for low-grade UTUC.
Dabogratinib is the only oral therapeutic candidate in clinical development for low-grade UTUC & aims to provide a kidney-sparing treatment option.
The collaboration seeks to address patient isolation, build a community, & encourage further education, advocacy, & research for UTUC.